Results: OPTI

Search articles by EPIC code

NEWSFLOW

OptiBiotix Health (#OPTI) – warns of product launches and restocking delays, expects sales normalising in H2

2022-08-24 07:39:46

views

OptiBiotix Health – ‘commercial and scientific update’, remains a strong buy

OptiBiotix Health (OPTI) has announced an update on recent scientific and commercial activities, emphasising it is “increasing the range of products, applications, and territories creating the potential to open larger market opportunities”.

By Tom Winnifrith and Steve Moore
2022-07-23 15:49:08

views

OptiBiotix Health – BUY, 50p first stop, 100p by next year

Writing on OptiBiotix Health (OPTI) last month with the shares at 21p to buy, we noted clear news flow potential to spark the shares. We drank our own medicine with Tom Winnifrith buying more shares in the market at c22p. They are now further up at 37p on the back of a “Joint development agreement signed with Firmenich”-titled announcement.

By Hotstockrockets
2022-07-16 17:51:24

views

OptiBiotix Health – agreement with Firmenich, remains a Strong Buy

Writing on OptiBiotix Health (OPTI) last month with the shares at 21p to buy, we noted potential for a move into meaningful profitability and further potential from 'second generation' products addressing much larger market opportunities. We drank our own medicine with Tom buying more shares at 22p. The shares are now further up at 31.5p on the back of a “Joint development agreement signed with Firmenich”-titled announcement.

By Tom Winnifrith & Steve Moore
2022-07-13 14:37:39

views

OptiBiotix Health – 2021 results: clear share price potential from here; STRONG BUY

OptiBiotix Health (OPTI) has announced results for the 2021 calendar year. It continues to make progress in its stated aims: to focus on a smaller number of large partners, and grow direct-to-consumer sales.

By Hotstockrockets
2022-07-01 11:27:50

NEWSFLOW

OptiBiotix Health (#OPTI) – 2021 revenue up to £2.2m, Op. loss £1.4m, argues subsequent “good progress”

2022-06-28 07:38:19

views

OptiBiotix Health – following recent developments, how does the valuation stack up?

Shares are now ‘ex-dividend' for Optibiotix's 'ProBiotix Health' business, which will be spun off onto the AQSE Growth Market - with an associated fundraise - at the end of this month. Additionally, SkinBioTherapeutics (SBTX), in which it has a 20.73% stake, has just announced half-year results - that the market did not like. So, how does the valuation stack up now?

By Tom Winnifrith & Steve Moore
2022-04-01 12:57:15

NEWSFLOW

OptiBiotix Health (#OPTI) – spins off probiotics business onto AQSE, with it raising £2.5m valuing it at £25.5m

2022-03-31 07:55:30

views

400% upside in Optibiotix shares - new Cenkos note

Cenkos is house broker to Optibiotix (OPTI) so it is biased. I own shed loads of shares so am biased. The forecasts in the note out today include sod all for the three major deals announced at Christmas. So they will be increased. Read into this what you want. My pension will be buying more shares at around the current level if it can.

By Tom Winnifrith
2022-03-30 13:59:56

views

OptiBiotix Health – intention to list its ProBiotix Health business on AQSE, Strong Buy…

OptiBiotix Health (OPTI) has announced that it intends to seek admission of its ProBiotix Health business onto the AQSE Growth Market with an associated fund raise of approximately £2.5 million at an indicative premoney valuation of £22.5 million and a distribution in specie. With, at a 35.5p share price, OptiBiotix as a whole currently capitalised at £31.3 million, is this good news? You bet!